Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Ambrx
Ambrx
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
You need to be a subscriber to read this article.
Click here
to find out more.
Pharmaceutical
A bullish time for biotech
Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Finance
Chinese consortium to acquire US biotech Ambrx
Group comprises Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech
Pharmaceutical
Ambrx hires Peter Kiener as Chief Scientific Officer
Brings expertise in development of next-generation biologic therapeutics to US firm
Research & Development
BMS partners Ambrx in up to US$112m ADC deal
To develop antibody drug candidates for cancer indications
Research & Development
Merck & Co collaborates with Ambrx
Will develop biologic drug conjugates using Ambrx protein technology
Subscribe now